CHRS Coherus Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—
Margins
Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%
Returns
ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x
Leverage & solvency
Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.27M | $14.31M | $12.31M | $12.75M | $11.57M | $10.25M | $7.60M | $7.73M |
| Cost of revenue | $4.09M | $4.24M | $3.81M | $4.04M | $3.72M | $3.40M | $2.65M | $2.75M |
| Gross profit | $10.18M | $10.06M | $8.50M | $8.70M | $7.85M | $6.86M | $4.95M | $4.98M |
| R&D expense | $22.61M | $21.44M | $21.54M | $30.97M | $27.25M | $26.31M | $24.36M | $20.76M |
| SG&A expense | $21.23M | $20.95M | $23.10M | $23.61M | $24.93M | $26.04M | $26.02M | $29.61M |
| Operating income | -$33.65M | -$32.33M | -$36.15M | -$45.88M | -$44.33M | -$45.49M | -$45.44M | -$45.38M |
| Interest expense | $2.78M | $2.32M | $2.19M | $2.25M | $2.33M | $2.28M | $2.15M | $1.91M |
| Pretax income | -$38.88M | -$33.35M | -$36.94M | -$46.35M | -$44.52M | -$44.86M | -$47.40M | -$46.09M |
| Net income | -$39.33M | -$20.63M | -$38.33M | -$37.64M | -$35.53M | $297.77M | -$56.57M | -$50.70M |
| EBITDA | -$32.80M | -$31.47M | -$35.27M | -$47.61M | -$44.03M | -$45.19M | -$44.39M | -$45.28M |
| EPS (basic) | -0.25 | -0.13 | -0.28 | — | -0.31 | 2.57 | -0.49 | — |
| EPS (diluted) | -0.25 | -0.13 | -0.28 | — | -0.31 | 2.57 | 2.57 | — |
| Weighted avg. shares (diluted) | 154.97M | 154.82M | 136.40M | — | 116.23M | 116.08M | 116.08M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $53.49M | $82.92M | $115.24M | $88.88M | $103.59M | $217.16M | $82.67M | $126.25M |
| Short-term investments | $30.14M | $22.38M | $51.81M | $83.25M | $88.31M | $20.74M | — | — |
| Receivables | $13.72M | $13.88M | $22.06M | $17.82M | $9.24M | $5.11M | $60.49M | $111.32M |
| Inventory | $4.82M | $5.67M | $4.83M | $3.17M | $2.05M | $4.51M | $3.52M | $4.21M |
| Current assets | $114.13M | $133.79M | $206.03M | $206.71M | $460.95M | $380.20M | $310.18M | $341.58M |
| PP&E, net | $652,000 | $865,000 | $1.09M | $1.34M | $1.63M | $1.91M | $2.26M | $2.58M |
| Intangibles | $18.12M | $18.75M | $19.38M | $20.00M | $20.62M | $23.45M | $24.12M | $24.79M |
| Total assets | $171.10M | $191.18M | $266.02M | $258.34M | $516.52M | $439.46M | $371.07M | $448.53M |
| Current liabilities | $75.64M | $75.51M | $132.33M | $140.39M | $372.30M | $263.63M | $255.04M | $282.98M |
| Total liabilities | $145.85M | $130.34M | $187.40M | $197.33M | $428.75M | $319.64M | $554.54M | $580.52M |
| Shareholders' equity | $25.25M | $60.84M | $78.62M | $61.01M | $87.77M | $119.83M | -$183.47M | -$131.99M |
| Shares outstanding | 154.53M | 154.47M | 154.22M | 121.15M | 116.24M | 116.22M | 115.91M | 115.61M |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.02M | -$62.09M | -$57.89M | -$19.72M | -$46.34M | -$46.63M | -$25.83M | $28.61M |
| Investing cash flow | -$7.61M | $29.63M | $30.66M | -$2.84M | -$67.23M | $462.64M | -$17.49M | -$542,000 |
| Financing cash flow | $12.05M | $144,000 | $53.59M | $8.08M | $2,000 | -$281.52M | -$264,000 | $231,000 |
| Depreciation & amortization | $853,000 | $862,000 | $881,000 | -$1.73M | $300,000 | $300,000 | $1.05M | $100,000 |
| Stock-based compensation | $3.68M | $2.58M | $2.38M | $2.78M | $3.39M | $5.42M | $5.37M | $6.38M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.